{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T01:07:06Z","timestamp":1764378426662,"version":"3.46.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cooper University Health Care"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-25384-8","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:29:23Z","timestamp":1763987363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA methyltransferase 1 correlates with immune modulation in pancreatic neuroendocrine tumors"],"prefix":"10.1038","volume":"15","author":[{"given":"Zena","family":"Saleh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel J.","family":"Nation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew C.","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Kalola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazid","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansa","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upasana","family":"Joneja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Spitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Ki","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"25384_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/pap.0000000000000201","volume":"26","author":"JM Guilmette","year":"2019","unstructured":"Guilmette, J. M. & Nos\u00e9, V. Neoplasms of the neuroendocrine pancreas: An update in the classification, definition, and molecular genetic advances. Adv. Anat. Pathol. 26, 13\u201330. https:\/\/doi.org\/10.1097\/pap.0000000000000201 (2019).","journal-title":"Adv. Anat. Pathol."},{"key":"25384_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ijc.27543","volume":"131","author":"C Zhou","year":"2012","unstructured":"Zhou, C., Zhang, J., Zheng, Y. & Zhu, Z. Pancreatic neuroendocrine tumors: A comprehensive review. Int. J. Cancer. 131, 1013\u20131022. https:\/\/doi.org\/10.1002\/ijc.27543 (2012).","journal-title":"Int. J. Cancer"},{"key":"25384_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","volume":"19","author":"TR Halfdanarson","year":"2008","unstructured":"Halfdanarson, T. R., Rabe, K. G., Rubin, J. & Petersen, G. M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol.: Of. J. Eur. Soc. Med. Oncol. 19, 1727\u20131733. https:\/\/doi.org\/10.1093\/annonc\/mdn351 (2008).","journal-title":"Annals Oncology: Official J. Eur. Soc. Med. Oncol."},{"key":"25384_CR4","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ejca.2011.10.030","volume":"48","author":"L Boninsegna","year":"2012","unstructured":"Boninsegna, L. et al. Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. Eur. J. Cancer (Oxford England: 1990). 48, 1608\u20131615. https:\/\/doi.org\/10.1016\/j.ejca.2011.10.030 (2012).","journal-title":"Eur. J. Cancer (Oxford England: 1990)"},{"key":"25384_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united States. JAMA Oncol. 3, 1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589 (2017).","journal-title":"JAMA Oncol."},{"key":"25384_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3322\/caac.21840","volume":"74","author":"A Chauhan","year":"2024","unstructured":"Chauhan, A. et al. Critical updates in neuroendocrine tumors: Version 9 American joint committee on cancer staging system for gastroenteropancreatic neuroendocrine tumors. Cancer J. Clin. 74, 359\u2013367. https:\/\/doi.org\/10.3322\/caac.21840 (2024).","journal-title":"Cancer J. Clin."},{"key":"25384_CR7","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.3748\/wjg.v26.i28.4036","volume":"26","author":"GB Mpilla","year":"2020","unstructured":"Mpilla, G. B., Philip, P. A., El-Rayes, B. & Azmi, A. S. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. World J. Gastroenterol. 26, 4036\u20134054. https:\/\/doi.org\/10.3748\/wjg.v26.i28.4036 (2020).","journal-title":"World J. Gastroenterol."},{"key":"25384_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/1751-2980.13123","volume":"23","author":"I Dogan","year":"2022","unstructured":"Dogan, I., Tastekin, D., Karabulut, S. & Sakar, B. Capecitabine and Temozolomide (CAPTEM) is effective in metastatic well-differentiated Gastrointestinal neuroendocrine tumors. J. Dig. Dis. 23, 493\u2013499. https:\/\/doi.org\/10.1111\/1751-2980.13123 (2022).","journal-title":"J. Dig. Dis."},{"key":"25384_CR9","doi-asserted-by":"publisher","unstructured":"Stueven, A. K. et al. Somatostatin analogues in the treatment of neuroendocrine tumors: Past, present and future. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20123049 (2019).","DOI":"10.3390\/ijms20123049"},{"key":"25384_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nrendo.2018.3","volume":"14","author":"M Frost","year":"2018","unstructured":"Frost, M., Lines, K. E. & Thakker, R. V. Current and emerging therapies for PNETs in patients with or without MEN1. Nat. Rev. Endocrinol. 14, 216\u2013227. https:\/\/doi.org\/10.1038\/nrendo.2018.3 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"25384_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi, M. et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103, 153\u2013171. https:\/\/doi.org\/10.1159\/000443171 (2016).","journal-title":"Neuroendocrinology"},{"key":"25384_CR12","doi-asserted-by":"publisher","unstructured":"Saleh, Z. et al. Pancreatic neuroendocrine tumors: signaling pathways and epigenetic regulation. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms25021331 (2024).","DOI":"10.3390\/ijms25021331"},{"key":"25384_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.surg.2022.12.008","volume":"173","author":"C Zhu","year":"2023","unstructured":"Zhu, C. et al. Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors. Surgery 173, 1045\u20131051. https:\/\/doi.org\/10.1016\/j.surg.2022.12.008 (2023).","journal-title":"Surgery"},{"key":"25384_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","volume":"17","author":"MJ Topper","year":"2020","unstructured":"Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R. & Baylin, S. B. The emerging role of epigenetic therapeutics in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 75\u201390. https:\/\/doi.org\/10.1038\/s41571-019-0266-5 (2020).","journal-title":"Nat. Reviews Clin. Oncol."},{"key":"25384_CR15","doi-asserted-by":"publisher","unstructured":"Yang, M. et al. World health organization grading classification for pancreatic neuroendocrine neoplasms: A comprehensive analysis from a large Chinese institution. BMC Cancer. 20 https:\/\/doi.org\/10.1186\/s12885-020-07356-5 (2020).","DOI":"10.1186\/s12885-020-07356-5"},{"key":"25384_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi, G. et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr. Pathol. 33, 115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2 (2022).","journal-title":"Endocr. Pathol."},{"key":"25384_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2217\/epi.09.44","volume":"2","author":"LA Cowan","year":"2010","unstructured":"Cowan, L. A., Talwar, S. & Yang, A. S. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with Azacitidine and decitabine in solid tumors. Epigenomics 2, 71\u201386. https:\/\/doi.org\/10.2217\/epi.09.44 (2010).","journal-title":"Epigenomics"},{"key":"25384_CR18","doi-asserted-by":"publisher","unstructured":"Maharjan, C. K. et al. Pancreatic neuroendocrine tumors: Molecular mechanisms and therapeutic targets. Cancers 13 https:\/\/doi.org\/10.3390\/cancers13205117 (2021).","DOI":"10.3390\/cancers13205117"},{"key":"25384_CR19","doi-asserted-by":"crossref","unstructured":"Hu, C., Liu, X., Zeng, Y., Liu, J. & Wu, F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: Mechanism and clinical application. Clin. Epigenet. 13 (2021).","DOI":"10.1186\/s13148-021-01154-x"},{"key":"25384_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel, B. & Schmid, J. A. The complexity of NF-\u03baB signaling in inflammation and cancer. Mol. Cancer. 12, 86. https:\/\/doi.org\/10.1186\/1476-4598-12-86 (2013).","journal-title":"Mol. Cancer"},{"key":"25384_CR21","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1158\/0008-5472.Can-15-1022","volume":"75","author":"T Lu","year":"2015","unstructured":"Lu, T. & Stark, G. R. NF-\u03baB: regulation by methylation. Cancer Res. 75, 3692\u20133695. https:\/\/doi.org\/10.1158\/0008-5472.Can-15-1022 (2015).","journal-title":"Cancer Res."},{"key":"25384_CR22","doi-asserted-by":"crossref","unstructured":"Mauro, C., Zazzeroni, F., Papa, S., Bubici, C. & Franzoso, G. In In inflammation and cancer: Methods and protocols: Volume 2: Molecular analysis and pathways. 169\u2013207 (eds Kozlov, S. V.) (Humana, 2009).","DOI":"10.1007\/978-1-60327-530-9_10"},{"key":"25384_CR23","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1038\/sj.onc.1209937","volume":"25","author":"ND Perkins","year":"2006","unstructured":"Perkins, N. D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25, 6717\u20136730. https:\/\/doi.org\/10.1038\/sj.onc.1209937 (2006).","journal-title":"Oncogene"},{"key":"25384_CR24","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1097\/pas.0000000000000089","volume":"37","author":"CM McCall","year":"2013","unstructured":"McCall, C. M. et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am. J. Surg. Pathol. 37, 1671\u20131677. https:\/\/doi.org\/10.1097\/pas.0000000000000089 (2013).","journal-title":"Am. J. Surg. Pathol."},{"key":"25384_CR25","doi-asserted-by":"publisher","unstructured":"Greenberg, J. et al. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. JCI Insight. 7 https:\/\/doi.org\/10.1172\/jci.insight.160130 (2022).","DOI":"10.1172\/jci.insight.160130"},{"key":"25384_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1615\/ForumImmunDisTher.2015014188","volume":"6","author":"J Lee","year":"2015","unstructured":"Lee, J., Ahn, E., Kissick, H. T. & Ahmed, R. Reinvigorating exhausted T cells by Blockade of the PD-1 pathway. Forum Immunopathol. Dis. Ther. 6, 7\u201317. https:\/\/doi.org\/10.1615\/ForumImmunDisTher.2015014188 (2015).","journal-title":"Forum Immunopathological Dis. Ther."},{"key":"25384_CR27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41416-020-0811-0","volume":"122","author":"K Okadome","year":"2020","unstructured":"Okadome, K. et al. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. Br. J. Cancer. 122, 1535\u20131543. https:\/\/doi.org\/10.1038\/s41416-020-0811-0 (2020).","journal-title":"Br. J. Cancer"},{"key":"25384_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13148-020-00883-9","volume":"12","author":"F Hoffmann","year":"2020","unstructured":"Hoffmann, F. et al. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clin. Epigenetics. 12, 94. https:\/\/doi.org\/10.1186\/s13148-020-00883-9 (2020).","journal-title":"Clin. Epigenetics"},{"key":"25384_CR29","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/2326-6066.Cir-20-0432","volume":"8","author":"AB Rodriguez","year":"2020","unstructured":"Rodriguez, A. B. & Engelhard, V. H. Insights into Tumor-Associated tertiary lymphoid structures: Novel targets for antitumor immunity and cancer immunotherapy. Cancer Immunol. Res. 8, 1338\u20131345. https:\/\/doi.org\/10.1158\/2326-6066.Cir-20-0432 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"25384_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/path.6241","volume":"262","author":"S Duan","year":"2024","unstructured":"Duan, S. et al. Spatial profiling reveals tissue-specific neuro-immune interactions in gastroenteropancreatic neuroendocrine tumors. J. Pathol. 262, 362\u2013376. https:\/\/doi.org\/10.1002\/path.6241 (2024).","journal-title":"J. Pathol."},{"key":"25384_CR31","doi-asserted-by":"publisher","first-page":"13166","DOI":"10.1038\/s41598-018-31383-9","volume":"8","author":"D Takahashi","year":"2018","unstructured":"Takahashi, D. et al. Profiling the tumour immune microenvironment in pancreatic neuroendocrine neoplasms with multispectral imaging indicates distinct subpopulation characteristics concordant with WHO 2017 classification. Sci. Rep. 8, 13166. https:\/\/doi.org\/10.1038\/s41598-018-31383-9 (2018).","journal-title":"Sci. Rep."},{"key":"25384_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/erc-17-0445","volume":"25","author":"T Hofving","year":"2018","unstructured":"Hofving, T. et al. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. Endocr. Relat. Cancer. 25, 367\u2013380. https:\/\/doi.org\/10.1530\/erc-17-0445 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"25384_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41590-024-02062-x","volume":"26","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Differential roles of human CD4\u2009+\u2009and CD8\u2009+\u2009regulatory T cells in controlling self-reactive immune responses. Nat. Immunol. 26, 230\u2013239. https:\/\/doi.org\/10.1038\/s41590-024-02062-x (2025).","journal-title":"Nat. Immunol."},{"key":"25384_CR34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Zhang, Z. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol. Immunol. 17, 807\u2013821. https:\/\/doi.org\/10.1038\/s41423-020-0488-6 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"25384_CR35","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.2147\/ott.S150817","volume":"11","author":"E Grywalska","year":"2018","unstructured":"Grywalska, E., Pasiarski, M., G\u00f3\u017ad\u017a, S. & Roli\u0144ski, J. Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. OncoTargets Therapy. 11, 6505\u20136524. https:\/\/doi.org\/10.2147\/ott.S150817 (2018).","journal-title":"OncoTargets Therapy"},{"key":"25384_CR36","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1158\/1078-0432.Ccr-18-1401","volume":"25","author":"L Cai","year":"2019","unstructured":"Cai, L. et al. Role of Tumor-Associated macrophages in the clinical course of pancreatic neuroendocrine tumors (PanNETs). Clin. Cancer Research: Official J. Am. Association Cancer Res. 25, 2644\u20132655. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1401 (2019).","journal-title":"Clin. Cancer Research: Official J. Am. Association Cancer Res."},{"key":"25384_CR37","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1002\/ijc.31562","volume":"143","author":"S Krug","year":"2018","unstructured":"Krug, S. et al. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors. Int. J. Cancer. 143, 1806\u20131816. https:\/\/doi.org\/10.1002\/ijc.31562 (2018).","journal-title":"Int. J. Cancer"},{"key":"25384_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0143-4179(91)90033-f","volume":"20","author":"MN Aparicio-Pag\u00e9s","year":"1991","unstructured":"Aparicio-Pag\u00e9s, M. N., Verspaget, H. W., Pe\u00f1a, A. S., Jansen, J. B. & Lamers, C. B. Natural killer cell activity in patients with neuroendocrine tumours of the Gastrointestinal tract; relation with Circulating Gastrointestinal hormones. Neuropeptides 20, 1\u20137. https:\/\/doi.org\/10.1016\/0143-4179(91)90033-f (1991).","journal-title":"Neuropeptides"},{"key":"25384_CR39","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/nm1649","volume":"13","author":"L Soucek","year":"2007","unstructured":"Soucek, L. et al. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13, 1211\u20131218. https:\/\/doi.org\/10.1038\/nm1649 (2007).","journal-title":"Nat. Med."},{"key":"25384_CR40","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1593\/neo.11980","volume":"13","author":"L Soucek","year":"2011","unstructured":"Soucek, L. et al. Modeling Pharmacological Inhibition of mast cell degranulation as a therapy for Insulinoma. Neoplasia (New York N Y). 13, 1093\u20131100. https:\/\/doi.org\/10.1593\/neo.11980 (2011).","journal-title":"Neoplasia (New York N Y)"},{"key":"25384_CR41","doi-asserted-by":"publisher","unstructured":"Du, N., Guo, F., Wang, Y. & Cui, J. N. K. Cell therapy: A rising star in cancer treatment. Cancers 13 https:\/\/doi.org\/10.3390\/cancers13164129 (2021).","DOI":"10.3390\/cancers13164129"},{"key":"25384_CR42","doi-asserted-by":"publisher","unstructured":"Aumer, T. et al. The type of DNA damage response after decitabine treatment depends on the level of DNMT activity. Life Sci. Alliance. 7 https:\/\/doi.org\/10.26508\/lsa.202302437 (2024).","DOI":"10.26508\/lsa.202302437"},{"key":"25384_CR43","doi-asserted-by":"publisher","unstructured":"Maslov, A. Y. et al. 5-Aza-2\u2032-deoxycytidine-induced genome rearrangements are mediated by DNMT1. Oncogene. 31, 5172\u20135179. https:\/\/doi.org\/10.1038\/onc.2012.9 (2012).","DOI":"10.1038\/onc.2012.9"},{"key":"25384_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13148-023-01534-5","volume":"15","author":"G Kerdivel","year":"2023","unstructured":"Kerdivel, G. et al. DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma. Clin. Epigenetics. 15, 121. https:\/\/doi.org\/10.1186\/s13148-023-01534-5 (2023).","journal-title":"Clin. Epigenetics"},{"key":"25384_CR45","doi-asserted-by":"publisher","first-page":"1989790","DOI":"10.1080\/2162402x.2021.1989790","volume":"10","author":"KC Huang","year":"2021","unstructured":"Huang, K. C. et al. DNMT1 constrains IFN\u03b2-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy. Oncoimmunology 10, 1989790. https:\/\/doi.org\/10.1080\/2162402x.2021.1989790 (2021).","journal-title":"Oncoimmunology"},{"key":"25384_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science. 348, 56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172 (2015).","journal-title":"Sci. (New York N Y)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25384-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25384-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25384-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T01:03:16Z","timestamp":1764378196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25384-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25384"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25384-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The experiment was conducted in accordance with the guidelines and approval by the Institutional Review Board (IRB) at Cooper University Hospital (IRB 23\u2013130). The collection, storage, and processing of PNET samples were carried out in strict accordance with the guidelines and regulations set by the IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"was waived by Cooper University Hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"41497"}}